Nabriva Therapeutics Announces Appointment of New CEO



    VIENNA, Austria, July 3 /CNW/ - Nabriva Therapeutics, a specialist in
antibiotics development, announces that Dr. George Golumbeski has been
appointed as Chief Executive Officer of the Company.
    Dr. Golumbeski brings to the team nearly twenty years of industry
experience serving most recently as Vice President of Business Development,
Licensing & Strategy for the oncology business unit at Novartis. In this
position he was responsible for the full array of business development
activities leading several transactions which have resulted in projects
currently in Phase III studies. While at Novartis, Dr. Golumbeski also served
as a member of the Executive Committee which oversees overall oncology
business performance. Prior to his tenure at Novartis, he led transactions
which have resulted in two products that have been approved or are in
registration in the US and the EU.
    "I am excited to join Nabriva at this important stage of its growth. The
Company's highly differentiated compounds have the potential to address the
significant need for new classes of effective antibiotics. Furthermore, the
team at Nabriva is highly experienced with a deep understanding and enthusiasm
for the development of novel antibiotics," commented Dr. Golumbeski.
    David Chiswell, Chair of the Supervisory Board, added, "We are pleased to
welcome George to the team. His leadership skills combined with his strategic
and business development insight will help position Nabriva as one of the
leading specialist companies in antibiotics development."

    About Nabriva Therapeutics:

    Headquartered in Vienna, Nabriva Therapeutics is engaged in the discovery
and development of innovative antibacterial agents addressing unmet medical
need in the hospital and community setting. The company has two compounds
currently in clinical trials and expects to have a third compound enter
clinical trials later this year. The lead compound, BC-3205, is a parenterally
and orally available pleuromutilin which is first in class and has significant
market potential in multiple indications (eg. SSSI & CAP). All of Nabriva's
programs are derived from compounds generated in-house through discovery
activity and the company maintains an ongoing effort in medicinal chemistry.

    The Company was founded in January 2006 as a spin-out of Sandoz GmbH
Kundl. The spin-out was led by Nomura Phase4 Ventures with a Series A
financing of EUR42 million with a syndicate that included HBM Partners, GLSV,
The Wellcome Trust and Novartis Venture Fund.





For further information:

For further information: Claudia Karner, Tel: +43(0)1-74093-1240,
e-mail: claudia.karner@nabriva.com

Organization Profile

NABRIVA THERAPEUTICS

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890